ReleaseWire Connect

RedHawk Holdings Corp. (OTCQB:IDNG) ("RedHawk" or the "Company") announced today that all three of its WoundClot Surgical – Advanced Bleeding Control ("WoundClot") offered products have been approved to participate in the Framework Agreement to Supply Wound Closure products, more commonly known as hemostats, to the National Health Service ("NHS") Supply Chain in the United Kingdom. This will allow for the WoundClot range of products to be listed within the NHS Supply Chain Catalogue ("Catalogue"), simplifying the procurement process and eliminating any barriers to evaluating the WoundClot range of products for use in all NHS hospitals. RedHawk said it expects WoundClot to be listed in the Catalogue on or about February 1, 2017 after NHS review and approval of the Company's quality management system.

RedHawk Holdings Corp. (OTCQB:IDNG) ("RedHawk" or the "Company") announced today that it will exit its real estate investments beginning in 2017. The Company said that it has achieved satisfactory returns on these investments and believes the invested capital can now be best utilized in other areas of the Company's business. The Company said that it expects to receive approximately $1.5 million from the sale of its real estate investments and will use the proceeds to retire approximately $0.25 million of existing real estate debt, provide working capital for its current operating business units and fund certain strategic transactions currently under consideration.

RedHawk Holdings Corp. (OTCQB:IDNG) ("RedHawk" or the "Company") announced today a consolidated net loss of $187,175 ($nil per share) on gross revenues of $499,280 for the three month period ended September 30, 2016. These first quarter results compare to a net loss $108,404 ($nil per share) on minimal revenues for the comparable three month period ended September 30, 2015.